Ani Pharmaceuticals (ANIP) Total Liabilities (2010 - 2026)
Ani Pharmaceuticals (ANIP) posted Total Liabilities of $859.7 million for Q1 2026, down 4.44% sequentially from $899.7 million in Q4 2025, and up 1.26% YoY from $849.0 million in Q1 2025.
Ani Pharmaceuticals (ANIP) Total Liabilities (2010 - 2026) Analysis & Trends
Ani Pharmaceuticals has reported Total Liabilities for 17 years, with the latest figure at $859.7 million in Q1 2026.
- Quarterly Total Liabilities rose 1.26% year-over-year to $859.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $859.7 million (up 1.26% YoY) and the FY2025 annual result came in at $899.7 million, up 5.11% from the prior year.
- Total Liabilities slipped to $859.7 million in Q1 2026 per ANIP's latest filing, from $899.7 million in the prior quarter.
- Over five years, Total Liabilities peaked at $902.3 million in Q3 2025 and troughed at $398.8 million in Q1 2022.
- A 5-year average of $608.9 million and a median of $440.1 million in 2024 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2025 and 2026: Total Liabilities jumped 100.25% in 2025, then gained 1.26% in 2026.
- Over 5 years, Total Liabilities stood at $421.5 million in 2022, then gained by 6.0% to $446.8 million in 2023, then jumped by 91.56% to $855.9 million in 2024, then advanced by 5.11% to $899.7 million in 2025, then retreated by 4.44% to $859.7 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $859.7 million, $899.7 million, and $902.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.85 Bn | 42.88 Bn | - | -21.66 Bn |
| 2 | Teva Pharmaceutical Industries | 43.02 Bn | 39.37 Bn | 2.15 Bn | 32.10 Bn |
| 3 | Zoetis | 31.47 Bn | 29.79 Bn | 1.05 Bn | 11.93 Bn |
| 4 | Takeda Pharmaceutical | 28.59 Bn | 22.79 Bn | 5.10 Bn | 50.85 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.53 Bn | 683.80 Mn | 819.80 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | 20.78 Bn |
| 7 | Neurocrine Biosciences | 15.45 Bn | 15.06 Bn | 935.80 Mn | 1.67 Bn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 6.97 Bn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | 2.12 Bn |
| 10 | Ani Pharmaceuticals | 1.63 Bn | 1.27 Bn | 165.89 Mn | 896.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 896.90 Mn |
| Mar 31, 2026 | 859.67 Mn |
| Dec 31, 2025 | 899.65 Mn |
| Sep 30, 2025 | 902.34 Mn |
| Jun 30, 2025 | 881.39 Mn |
| Mar 31, 2025 | 848.96 Mn |
| Dec 31, 2024 | 855.94 Mn |
| Sep 30, 2024 | 856.58 Mn |
| Jun 30, 2024 | 440.14 Mn |
| Mar 31, 2024 | 437.71 Mn |
| Dec 31, 2023 | 446.82 Mn |
| Sep 30, 2023 | 435.20 Mn |
| Jun 30, 2023 | 424.87 Mn |
| Mar 31, 2023 | 425.74 Mn |
| Dec 31, 2022 | 421.55 Mn |
| Sep 30, 2022 | 402.44 Mn |
| Jun 30, 2022 | 414.38 Mn |
| Mar 31, 2022 | 398.75 Mn |
| Dec 31, 2021 | 412.86 Mn |
| Sep 30, 2021 | 279.05 Mn |